FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013602834> ?p ?o ?g. }

• W2013602834 endingPage "49K" @default.
• W2013602834 startingPage "42K" @default.
• W2013602834 abstract "Trimetazidine has an anti-ischemic effect in angina pectoris. This agent has no hemodynamic effects, and its benefit is presumed to be based on a metabolic mechanism of action. A group of 33 dogs undergoing open-chest left anterior descending coronary artery (LAD) ligation causing prolonged ischemia were imaged with quantitative positron emission tomography (PET) using 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) to measure regional glucose metabolic utilization (rGMU) and [11C]acetate to measure regional monoexponential washout rate constant (Kmono) for oxidative metabolism in nonrisk and ischemic-risk myocardium. A total of 20 dogs were pretreated with trimetazidine at low dose (n = 10, 1 mg/kg) and high dose (n = 10, 5 mg/kg) and compared with 13 control dogs. Microsphere-measured myocardial blood flow (mL/min/g) was measured preocclusion and repeated hourly after occlusion and expressed as a ratio of preocclusion myocardial blood flow to verify a stable level of ischemia during PET. No differences were seen in postocclusion ischemic risk/nonrisk myocardial blood flow between treatment groups (p = not significant [NS]). Preocclusion and hourly measurements of heart rate and blood pressure corrected for baseline revealed no difference in control dogs versus trimetazidine (low-dose and high-dose) groups (p = NS). 18FDG-derived rGMU (μmol/min/g) was increased in high-dose trimetazidine versus control dogs in nonrisk and ischemic risk groups, respectively (1.16 ± 0.57 vs 0.51 ± 0.38 and 0.43 ± 0.29 vs 0.20 ± 0.14; p <0.05). rGMU was increased proportionately in nonrisk and ischemic risk in all groups without significant differences when corrected for nonrisk rGMU (ischemic risk/nonrisk was 0.92 ± 1.3 vs 0.64 ± 0.66 vs 0.40 ± 0.22 for control dogs, all trimetazidine and high-dose trimetazidine groups). Kmono (min−1) was not altered in any group (nonrisk = 0.13 ± 0.03 vs 0.13 ± 0.03 vs 0.14 ± 0.02 and ischemic risk = 0.18 ± 0.05 vs 0.17 ± 0.06 vs 0.16 ± 0.06 for control dogs, all trimetazidine and high-dose trimetazidine groups, respectively; p = NS for nonrisk vs ischemic risk, between and within groups). Our data verify that trimetazidine does not alter hemodynamic parameters. It increases total glucose utilization (oxidative and glycolytic) in myocardium without preferential increase in ischemic tissue. Absence of change in total oxidative metabolism suggests increased glucose metabolism is predominantly glycolysis or an increase in glucose oxidation with similar decrease in fatty acid oxidation." @default.
• W2013602834 created "2016-06-24" @default.
• W2013602834 creator A5002243330 @default.
• W2013602834 creator A5005714613 @default.
• W2013602834 creator A5008242380 @default.
• W2013602834 creator A5012255788 @default.
• W2013602834 creator A5016792094 @default.
• W2013602834 creator A5023581595 @default.
• W2013602834 creator A5032506650 @default.
• W2013602834 creator A5037182975 @default.
• W2013602834 date "1998-09-01" @default.
• W2013602834 modified "2023-10-12" @default.
• W2013602834 title "Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography" @default.
• W2013602834 cites W1745842455 @default.
• W2013602834 cites W1974048083 @default.
• W2013602834 cites W1977567372 @default.
• W2013602834 cites W1984863905 @default.
• W2013602834 cites W1986461872 @default.
• W2013602834 cites W1988377552 @default.
• W2013602834 cites W1989705400 @default.
• W2013602834 cites W2004418313 @default.
• W2013602834 cites W2008437352 @default.
• W2013602834 cites W2017733551 @default.
• W2013602834 cites W2024534607 @default.
• W2013602834 cites W2029110864 @default.
• W2013602834 cites W2037347467 @default.
• W2013602834 cites W2042144420 @default.
• W2013602834 cites W2046991068 @default.
• W2013602834 cites W2052129674 @default.
• W2013602834 cites W2090306035 @default.
• W2013602834 cites W2092047671 @default.
• W2013602834 cites W2094607582 @default.
• W2013602834 cites W2101881994 @default.
• W2013602834 cites W2124009251 @default.
• W2013602834 cites W2164796444 @default.
• W2013602834 cites W303812557 @default.
• W2013602834 cites W50124930 @default.
• W2013602834 doi "https://doi.org/10.1016/s0002-9149(98)00536-0" @default.
• W2013602834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9737485" @default.
• W2013602834 hasPublicationYear "1998" @default.
• W2013602834 type Work @default.
• W2013602834 sameAs 2013602834 @default.
• W2013602834 citedByCount "38" @default.
• W2013602834 countsByYear W20136028342012 @default.
• W2013602834 countsByYear W20136028342014 @default.
• W2013602834 countsByYear W20136028342015 @default.
• W2013602834 countsByYear W20136028342016 @default.
• W2013602834 countsByYear W20136028342019 @default.
• W2013602834 countsByYear W20136028342021 @default.
• W2013602834 crossrefType "journal-article" @default.
• W2013602834 hasAuthorship W2013602834A5002243330 @default.
• W2013602834 hasAuthorship W2013602834A5005714613 @default.
• W2013602834 hasAuthorship W2013602834A5008242380 @default.
• W2013602834 hasAuthorship W2013602834A5012255788 @default.
• W2013602834 hasAuthorship W2013602834A5016792094 @default.
• W2013602834 hasAuthorship W2013602834A5023581595 @default.
• W2013602834 hasAuthorship W2013602834A5032506650 @default.
• W2013602834 hasAuthorship W2013602834A5037182975 @default.
• W2013602834 hasConcept C126322002 @default.
• W2013602834 hasConcept C158846371 @default.
• W2013602834 hasConcept C164705383 @default.
• W2013602834 hasConcept C178853913 @default.
• W2013602834 hasConcept C2775842073 @default.
• W2013602834 hasConcept C2776268601 @default.
• W2013602834 hasConcept C2776894844 @default.
• W2013602834 hasConcept C2777927741 @default.
• W2013602834 hasConcept C2989005 @default.
• W2013602834 hasConcept C42219234 @default.
• W2013602834 hasConcept C541997718 @default.
• W2013602834 hasConcept C71924100 @default.
• W2013602834 hasConceptScore W2013602834C126322002 @default.
• W2013602834 hasConceptScore W2013602834C158846371 @default.
• W2013602834 hasConceptScore W2013602834C164705383 @default.
• W2013602834 hasConceptScore W2013602834C178853913 @default.
• W2013602834 hasConceptScore W2013602834C2775842073 @default.
• W2013602834 hasConceptScore W2013602834C2776268601 @default.
• W2013602834 hasConceptScore W2013602834C2776894844 @default.
• W2013602834 hasConceptScore W2013602834C2777927741 @default.
• W2013602834 hasConceptScore W2013602834C2989005 @default.
• W2013602834 hasConceptScore W2013602834C42219234 @default.
• W2013602834 hasConceptScore W2013602834C541997718 @default.
• W2013602834 hasConceptScore W2013602834C71924100 @default.
• W2013602834 hasIssue "5" @default.
• W2013602834 hasLocation W20136028341 @default.
• W2013602834 hasLocation W20136028342 @default.
• W2013602834 hasOpenAccess W2013602834 @default.
• W2013602834 hasPrimaryLocation W20136028341 @default.
• W2013602834 hasRelatedWork W1991861873 @default.
• W2013602834 hasRelatedWork W2013602834 @default.
• W2013602834 hasRelatedWork W2035928331 @default.
• W2013602834 hasRelatedWork W2039082344 @default.
• W2013602834 hasRelatedWork W2040748468 @default.
• W2013602834 hasRelatedWork W2091343426 @default.
• W2013602834 hasRelatedWork W2154954671 @default.
• W2013602834 hasRelatedWork W2375721956 @default.
• W2013602834 hasRelatedWork W2390572113 @default.
• W2013602834 hasRelatedWork W3141787527 @default.
• W2013602834 hasVolume "82" @default.

• next